Molecular markers as therapeutic targets in lung cancer / 癌症
Chinese Journal of Cancer
;
(12): 59-62, 2013.
Article
in English
| WPRIM
| ID: wpr-295807
ABSTRACT
Lung cancer is responsible for 29% of cancer deaths in the United States and has very low 5-year survival rates of approximately 11% in men and 15% in women. Although the early diagnosis of lung cancer may increase the survival rate with adequate treatment, advanced lung cancers are often metastasized and receive limited benefit from therapeutic regimens. As conventional treatments for lung cancer reach their limitations, researchers have attempted to discover novel drug therapies aimed at specific targets contributing to the progression of tumorigenesis. Recent advances in systems biology have enabled the molecular biology of lung carcinogenesis to be elucidated. Our understanding of the physiologic processes of tumor development provide a means to design more effective and specific drugs with less toxicity, thereby accelerating the delivery of new drug therapies to the patient's bedside.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Proto-Oncogene Proteins p21(ras)
/
Proto-Oncogene Proteins
/
Drug Delivery Systems
/
Carcinoma, Small Cell
/
Carcinoma, Non-Small-Cell Lung
/
Ras Proteins
/
Therapeutic Uses
/
Protein Kinase Inhibitors
/
Drug Therapy
/
Molecular Targeted Therapy
Type of study:
Screening study
Limits:
Humans
Language:
English
Journal:
Chinese Journal of Cancer
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS